Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III study of STI571 versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in patients with newly diagnosed, previously untreated, Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).

Next Previous
X
Search
Trial Profile

A phase III study of STI571 versus interferon-alpha (IFN-alpha) combined with cytarabine (Ara-C) in patients with newly diagnosed, previously untreated, Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia in chronic phase (CML-CP).

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imatinib (Primary) ; Cytarabine; Interferon alpha
  • Indications Chronic myeloid leukaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms IRIS
  • Sponsors Novartis Pharmaceuticals Corporation

    • Most Recent Events

    • 09 Mar 2017 11 year follow up results assessing long term safety and efficacy published in the New England Journal of Medicine.
    • 06 Jun 2012 New source identified and integrated (German Clinical Trials Register DRKS00003841).
    • 14 Sep 2010 Planned end date (January 2012) added as reported by ClinicalTrials.gov. record NCT00333840.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top